• Call +1.858.633.0165 or Fax +1.858.633.0166 or Contact Us

Bevacizumab Inhibitor

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS5759549

Ipilimumab anti-CTLA-4) is an immunomodulatory monoclonal antibody directed against the cell surface antigen CTLA-4 and also a type of immune checkpoint inhibitor. Bevacizumab a humanized monoclonal antibody specifically binds to all VEGF-A isoforms with high… More details

Product Documentation
PDF
Sample Manual Insert View PDF
PDF
Testing Data View PDF
PDF
Certificate of Analysis (COA) View PDF
PDF
QC Report View PDF
PDF
Material Safety Data Sheet View PDF
PDF
Technical Datasheet View PDF
PDF
Protocol View PDF

Product Overview

Online Datasheet in PDF
Product Name
Bevacizumab, Inhibitor
Full Product Name
Bevacizumab
Product Synonym Names
Bevacizumab(anti-VEGF); anti-VEGF; rhuMab VEGF
Form/Format
PBS, PH 7.2
Purity/Purification
98% (SEC - HPLC)
Concentration
27.1 mg/mL (lot specific)
Preparation and Storage
Store at -20°C . Dry ice.
Molecular Weight
149 kDa
CAS Number
216974-75-3
Target IC50
VEGFR
Cell Research
Human umbilical vein endothelial cells (HUVECs) (1x104 cells/100uL/well) are seeded in 96-well plates and cultured at 37 for 14 h with Endothelial Cell Medium supplemented with 5% heat-inactivated FCS, 100 U/mL Penicillin, 100 U/mL Streptomycin, and endothelial cell growth supplement. After low-serum starvation overnight, cells are treated with different concentrations of FD006 or Bevacizumab which are pre-incubated with 10ng/mL VEGF for 30 minutes and incubated at 37, 5% CO2 for 72 hours. Then, 10uL CCK8 is added to each well and incubated for another 4 hours. The absorbance is measured by spectrophotometer at 450nM to determine the cell viability[2]. Cell lines: HUVECs
Kinase Assay
The binding kinetics of Bevacizumab or FD006 to VEGF is measured using Bio-Layer Inter-Ferometry on Octet RED. The assay is conducted at 30 degree C in PBS buffer. Sensor tips are pre-wet for 15 mins in buffer immediately prior to use, and the microplates are filled with 200uL per well of diluted samples (VEGF) or buffer and agitated at 1000rpm. The anti-human IgG biosensor are pre-saturated with Bevacizumab or FD006 (10ug/mL) and washed in buffer for 120 seconds, and then transferred to VEGF at concentrations of 10ug/mL, 3ug/mL and 1ug/mL. The VEGF association and dissociation rates are measured for 5mins and 10mins, respectively. The Kinetics parameters (Kon and Koff) and affinities (KD) are calculated from a non-linear global fit using the Octet analysis software. Multiple independent measurements are performed[2].
Dry Ice Shipment
Extra charge fee may add to your shipping cost as dry ice is required to ship this product.

Product Categories/Family for Bevacizumab, inhibitor

Product References and Citations for Bevacizumab, inhibitor

Tan H, et al. 99mTc-labeled bevacizumab for detecting atherosclerotic plaque linked to plaque neovascularization and monitoring antiangiogenic effects of atorvastatin treatment,in ApoE-/-mice. Sci Rep. 2017 Jun 14;7(1):3504.
Tan H, et al. 99mTc-labeled bevacizumab for detecting atherosclerotic plaque linked to plaque neovascularization and monitoring antiangiogenic effects of atorvastatin treatment,in ApoE-/-mice. Sci Rep. 2017 Jun 14;7(1):3504.
Wang Q, et al. Pharmacological characteristics and efficacy of a novel anti-angiogenic antibody FD006 in corneal neovascularization. BMC Biotechnol. 2014 Feb 27;14:17.
Wang Q, et al. Pharmacological characteristics and efficacy of a novel anti-angiogenic antibody FD006 in corneal neovascularization. BMC Biotechnol. 2014 Feb 27;14:17.
Di Mauro C, et al. Hedgehog signalling pathway orchestrates angiogenesis in triple-negative breast cancers. Br J Cancer. 2017 May 23;116(11):1425-1435.
Di Mauro C, et al. Hedgehog signalling pathway orchestrates angiogenesis in triple-negative breast cancers. Br J Cancer. 2017 May 23;116(11):1425-1435.

Other Notes

Small volumes of Bevacizumab, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Searchable Terms for Bevacizumab purchase

MBS5759549 is an inhibitor targeting Bevacizumab.
Request a Quote

Please fill out the form below and our representative will get back to you shortly.

MBS000000
Contact Us

Please fill out the form below and our representative will get back to you shortly.

MBS000000